EIF3K and myeloid sarcoma: Additionally, anti-hnRNP A1-M9 antibodies, in the setting of a pro-inflammatory environment (EAE), lead to the development of hind limb spasticity and neurodegeneration, including axonal dying back, phenotypes both observed in HSP and MS [20,75,76].